ArticleJournal of cancer research and clinical oncology2026
Development of radiolabeled
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current study aims to develop a clinically applicable radiopharmaceutical agent for long-term imaging in the diagnosis and management of oncologic patients in the field of nuclear medicine. Liposomes, as pharmaceutical nanocarriers, have been extensively studied in pharmaceutical industry and depending on their structural characteristics could be formulated for accumulation in various pathological sites in the body. PEGylated liposomes have smaller volume of distribution and decreased clearance, consequently, due to their more prolonged presence in the bloodstream and their stability during this time, could be used for tumor imaging. STUDY DESIGN AND
methodsIn this work, liposomal formulations encapsulating albumin were synthesized by thin-film hydration technique, then extruded and after homogenization, their characteristics including size, zeta potential and encapsulation efficiency were measured. Then, these liposomes were labeled by
resultsThe result of our study displayed that
conclusionsOur in vitro and in vivo studies demonstrated that this PEGylated radiolabeled liposomal formulation have considerable stability and efficiency for long-term tumor imaging which merit further studies for its transformation into clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.